Table 2 Characteristics of the whole cohort: stage III breast tumor vs control participants (benign disease of the breast pooled with stage 0 breast cancer)
From: Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
Variable | Control (n = 23) Benign and Stage 0 | Case (n = 23) Stage III | Case–Control comparison p-values | |||
|---|---|---|---|---|---|---|
Mean ± SD | Median ± IQR | Mean ± SD | Median ± IQR | Unpaired | Paired | |
Age (years) | 54 | 54 | 55 | 54 | 0.86† | 0.12₮ |
± 7.7 | [50; 62] | ± 7.3 | [51; 62] | |||
BMI (kg/m2) | 25.2 | 24.7 | 26.2 | 25.7 | 0.46† | 0.45₮ |
± 4.3 | [21.4; 30.0] | ± 4.6 | [23.1; 28.4] | |||
Triglycerides (mmol/L) | 1.5 | 1.3 | 1.5 | 1.5 | 0.33‡ | 0.77₩ |
± 1.0 | [0.8; 1.7] | ± 0.5 | [1.2; 1.5] | |||
Cholesterol (mmol/L) | 5.1 | 5.1 | 5.0 | 5.1 | 0.77‡ | 0.79₩ |
± 0.8 | [4.7; 5.4] | ± 1.0 | [4.1; 5.6] | |||
HDL-C (mmol/L) | 1.5 | 1.5 | 1.5 | 1.4 | 0.77† | 0.75₮ |
± 0.4 | [1.2; 1.8] | ± 0.4 | [1.2; 1.7] | |||
LDL-C (mmol/L) | 2.9 | 3.0 | 2.9 | 2.7 | 0.90† | 0.92₮ |
± 1.0 | [2.3; 3.4] | ± 0.8 | [2.1; 3.6] | |||
Non-HDL (mmol/L) | 3.6 | 3.5 | 3.6 | 3.6 | 0.87† | 0.89₮ |
± 0.9 | [3.0; 4.0] | ± 0.9 | [2.6; 4.3] | |||
Apo B (g/L) | 1.0 | 1.0 | 1.0 | 1.0 | 0.87† | 0.88₮ |
± 0.3 | [0.8; 1.1] | ± 0.2 | [0.8; 1.1] | |||
Lp(a) (nmol/L) | 67 | 42 | 94 | 35 | 0.97‡ | 0.51₩ |
± 72.9 | [13; 136] | ± 117.1 | [12; 169] | |||
PCSK9 (ng/mL) | 87.0 | 81.7 | 98.9 | 97.9 | 0.056‡ | 0.065₩ |
± 29.8 | [67.5; 104.2] | ± 23.5 | [84.1; 117.5] | |||
ANGPTL3 (ng/mL) | 98.0 | 95.0 | 108.2 | 104.1 | 0.36† | 0.33₮ |
± 34.0 | [70.0; 131.3] | ± 41.5 | [85.3; 130.9] | |||
Non-fasting C-peptide (pmol/L) | 808 | 856 | 799 | 652 | 0.81‡ | 0.99₩ |
± 466 | [398; 1066] | ± 500.3 | [437; 1088] | |||
Non-fasting Insulin (pmol/L) | 112 | 106 | 121 | 72 | 0.95‡ | 0.75₩ |
± 89.7 | [31; 160] | ± 114 | [37; 218] | |||